AMRANE Karim

2.4K posts

AMRANE Karim banner
AMRANE Karim

AMRANE Karim

@AMRANEKarim6

Medical Oncologist MD-PhD, DITEP @Gustaveroussy

Villejuif, France Katılım Şubat 2021
158 Takip Edilen81 Takipçiler
AMRANE Karim retweetledi
Dr Rishabh Jain
Dr Rishabh Jain@DrRishabhOnco·
#ASCO26 7 years later… the median PFS with lorlatinib is STILL not reached in advanced ALK+ NSCLC. CROWN continues to deliver one of the most durable targeted therapy signals ever seen in solid tumors. 🧬 CROWN Trial Lorlatinib vs Crizotinib 1L advanced ALK+ NSCLC 📌 Key results: • Median PFS: NR vs 9.1 mo • HR 0.19 • 7-year PFS: 55% vs 3% • No new intracranial progression after 30 months on lorlatinib 🧠 Most striking finding: Patients progression-free at 24 months had a 79% chance of remaining progression-free at year 7. 44% of patients are STILL on lorlatinib at 7 years. Despite higher grade 3/4 AEs (77%), discontinuation due to TRAEs remained low: • 5% lorlatinib • 6% crizotinib This is no longer just “disease control.” For many ALK+ patients, this is beginning to resemble long-term functional remission. 📖 Full abstract in comment ⬇️ #OncoTwitter #MedTwitter #LungCancer #NSCLC #ALK @asco @myesmo @esmo_open @OncoAlert @larvol
Dr Rishabh Jain tweet media
Dr Rishabh Jain@DrRishabhOnco

🫁 THE 10 MOST IMPORTANT LUNG CANCER TRIALS OF #ASCO26 🎯 TARGETED THERAPY MOVES EARLIER 1️⃣ LIBRETTO-432 (LBA3) Adjuvant selpercatinib in resected RET+ NSCLC Precision medicine officially enters curative-intent RET disease. 2️⃣ NeoADAURA Neoadjuvant osimertinib ± chemotherapy in EGFR-mutant NSCLC Targeted therapy keeps moving earlier. 3️⃣ CROWN 7-Year Update Lorlatinib vs crizotinib in ALK+ NSCLC Are we finally seeing a true survival plateau? 4️⃣ MARIPOSA Updated OS Amivantamab + lazertinib vs osimertinib The efficacy vs toxicity debate continues. 5️⃣ Beamion LUNG-1 CNS Cohort Zongertinib in HER2-mutant NSCLC Critical intracranial activity data. 🧬 FRONTLINE PRECISION EXPANSION 6️⃣ SUNVOZERTINIB 1L Frontline uncommon EGFR-mutant NSCLC A huge unmet-need population. 7️⃣ Olomorasib 1L Cohort Second-generation KRAS G12C inhibition moves upfront KRAS continues evolving rapidly. 🔥 IMMUNOLOGY & BISPECIFICS 8️⃣ HARMONi-6 (LBA4) Ivonescimab + chemo vs tislelizumab + chemo PD-1/VEGF bispecifics enter frontline squamous NSCLC. 9️⃣ DeLLphi-312 Tarlatamab in 1L ES-SCLC Potentially practice-changing if positive. 🔟 IMforte Subtype Analysis Can molecular SCLC subtypes finally guide maintenance therapy? Which thoracic abstract are you watching most closely? 👀 #LungCancer #LCSM #OncTwitter #MedTwitter #ASCO26 @ASCO @IASLC @myesmo @esmo_open @OncoAlert

English
3
31
84
7.5K
AMRANE Karim retweetledi
Aakash Desai, MD, MPH, FASCO
Aakash Desai, MD, MPH, FASCO@ADesaiMD·
@ASCO #ASCO26 data we will see the data for Silevertinib (BDTX-1535) in treatment-naive non-classical EGFR NSCLC: ➡️ ORR 60%. ➡️ DCR 91%. ➡️ CNS ORR 86%. ➡️ mPFS 15.2 months.
 Non-classical EGFR mutations (~30% of EGFR NSCLC) have been the forgotten population poor responses to standard TKIs, limited trial options. Silevertinib changes that calculus. Rapid Oral Abstract at #ASCO26, May 30 presentation by @JuliaRotow Proud to be a part of this important study! @ONealCancerUAB
Aakash Desai, MD, MPH, FASCO tweet media
English
0
11
32
1.7K
AMRANE Karim retweetledi
Hidehito HORINOUCHI
Hidehito HORINOUCHI@HHorinouchi·
🆙 #ASCO26 #LCSM Rapid Oral 🔥TSN1611 (Oral KRAS G12D ON/OFF Inhibitor) in KRAS G12D+ NSCLC ✅ORR 50%, DCR 90% ✅9m PFS rate 54.5% 🎙️Dr. Yongfeng Yu 🔢8516 ☑️NCT06385925 🔗 asco.org/abstracts-pres… @OncoAlert @Larvol @ASCO @KRASKickers
Hidehito HORINOUCHI tweet media
Hidehito HORINOUCHI@HHorinouchi

🆙 #ASCO26 #LCSM Rapid Oral Abstract Session 🔥TSN1611 (Oral KRAS G12D Inhibitor): Phase 1/2 Efficacy and Safety in KRAS G12D–Mutated NSCLC 🎙️Dr. Yongfeng Yu 🔢8516 ☑️NCT06385925 🔗 asco.org/abstracts-pres… @OncoAlert @Larvol @ASCO

English
0
1
4
774
AMRANE Karim retweetledi
Hidehito HORINOUCHI
Hidehito HORINOUCHI@HHorinouchi·
🆙 #ASCO26 #LCSM Rapid Oral 🔥ROSETTA Lung-02: Pumitamig (PD-L1×VEGF-A bsAb) + Chemo in 1L NSCLC ✅ORR 70.0% ✅NSQ ORR 66.7%, SQ ORR 73.7% ✅Active across all PD-L1 levels 🎙️ @peters_solange 🔢8513 ☑️NCT06712316 🔗 asco.org/abstracts-pres… @OncoAlert @Larvol @ASCO
Hidehito HORINOUCHI tweet media
Hidehito HORINOUCHI@HHorinouchi

🆙 #ASCO26 #LCSM Rapid Oral Abstract Session 🔥ROSETTA Lung-02: Pumitamig (PD-L1 × VEGF-A bsAb) + Chemotherapy in 1L NSCLC 🎙️ @peters_solange 🔢8513 ☑️NCT06712316 🔗 asco.org/abstracts-pres… @OncoAlert @Larvol @ASCO

English
0
11
18
3K
AMRANE Karim retweetledi
Dr Rupam Manna MD
Dr Rupam Manna MD@DrRupamOncology·
🧬 FAPI PET is redefining the future of cancer imaging. Unlike FDG PET, which visualizes tumor glucose metabolism, FAPI PET maps the tumor microenvironment — especially cancer-associated fibroblasts (CAFs) and stromal activity. Why this matters clinically 👇 ✅ Better tumor-to-background contrast ✅ Superior detection of peritoneal disease ✅ Improved visualization of desmoplastic tumors ✅ Better assessment of low-FDG tumors ✅ Potential role in radiotherapy contouring ✅ Emerging theranostic applications (^177Lu-FAPI) The shift in oncology imaging is happening: ➡️ From “tumor metabolism imaging” ➡️ To “tumor ecosystem imaging” #FAPIPET #PETCT #NuclearMedicine #MedicalOncology #CancerImaging #Radiology #Oncology #PrecisionOncology #Theranostics #RadiationOncology #PancreaticCancer #GastricCancer #BreastCancer #HeadAndNeckCancer #CancerResearch #DrRupamManna #CancerConceptsExplained
Dr Rupam Manna MD tweet media
English
0
27
63
2.4K
AMRANE Karim retweetledi
MV Chandrakanth
MV Chandrakanth@ChandrakanthMv·
Desmoid tumors are “benign” histologically — but clinically aggressive, painful, and difficult to control. At #ASCO2026, the Phase 3 RINGSIDE trial showed major activity with the oral γ-secretase inhibitor (GSI) varegacestat: • HR 0.16 for progression • ORR 56% vs 9% • Deep tumor shrinkage • Meaningful pain improvement What is a GSI? Gamma-secretase inhibitors block NOTCH signaling, a key pathway involved in desmoid tumor biology. Nirogacestat first established GSIs as an effective strategy in desmoid tumors. Now varegacestat further strengthens this class with impressive efficacy and durable control. Toxicity management remains important — especially diarrhea and ovarian dysfunction. #MVOnco #ASCO2026 #DesmoidTumor #Sarcoma #Oncology #MedicalOncology #TargetedTherapy #Nirogacestat #Varegacestat #OncTwitter
MV Chandrakanth tweet media
English
0
15
35
1.7K
AMRANE Karim retweetledi
Hidehito HORINOUCHI
Hidehito HORINOUCHI@HHorinouchi·
🆙 #ASCO26 #LCSM Oral 🔥Lunbotinib: Phase 2 in RET Fusion+ NSCLC ✅Pre-tx: ORR 87.1%, mPFS 27.5m ✅TKI-naïve: ORR 81.3%, mPFS NR ✅IC-ORR 82.6%/75.0% (pre-tx/naïve) 🎙️Dr. Qing Zhou 🔢8505 ☑️NCT05265091 🔗 asco.org/abstracts-pres… @OncoAlert @Larvol @ASCO @RetRenegades
Hidehito HORINOUCHI tweet media
Hidehito HORINOUCHI@HHorinouchi

🆙 #ASCO26 #LCSM Oral Abstract Session 🔥Lunbotinib (A400/EP0031): Efficacy and Safety of a Next-Generation Selective RET Inhibitor in Advanced RET Fusion–Positive NSCLC 🎙️Dr. Qing Zhou 🔢8505 ☑️NCT05265091 🔗 asco.org/abstracts-pres… @OncoAlert @Larvol @ASCO

Français
1
10
19
2.8K
AMRANE Karim retweetledi
d.planchard
d.planchard@dplanchard·
Thrilled to discuss the critical role of HER2 testing in NSCLC & the impressive monotherapy activity of ADCs (like T-DXd) from our Phase 1b DESTINY-Lung03 trial! @JTOonline Grateful to an amazing team of co-authors! Clink the link to read 👇 @IASLC #Lungcancer #HER2
JTO & JTO CRR@JTOonline

According to DESTINY-Lung03, T-DXd showed durable antitumor activity and a manageable safety profile in previously treated HER2 IHC 3+/2+ #NSCLC, supporting routine #HER2 IHC testing in diagnostic workup. Read more: bit.ly/4dai726

English
1
5
20
2.1K
AMRANE Karim retweetledi
Aakash Desai, MD, MPH, FASCO
Aakash Desai, MD, MPH, FASCO@ADesaiMD·
👑 CROWN at 7 years. ➡️ Lorlatinib median PFS: still not reached. 7-yr PFS: 55% vs 3%. HR 0.19.
 Event-free at 2 years → 79% still progression-free at year 7.
 Zero new brain metastases after month 30. IC HR 0.06. Only 5% discontinued for TRAEs. I think this is what it is for a meaningful subset of ALK+ patients: functional cure. Really exciting! For me today most patients should be getting lorlatinib 1L for @ALKPositiveinc @LungCancerRx @ASCO #ASCO26
Aakash Desai, MD, MPH, FASCO tweet media
English
0
15
28
4.9K
AMRANE Karim retweetledi
Hidehito HORINOUCHI
Hidehito HORINOUCHI@HHorinouchi·
🆙 #ASCO26 #LCSM Oral 🔥Ivonescimab + Liposomal Irinotecan in 2L SCLC after ChemoICI ✅6m PFS 72.0% ✅mPFS 9.8mo, ORR 61.7% ✅Grade ≥3 TRAEs 26.7%; no TRD 🎙️Dr. Yun Fan 🔢8007 ☑️NCT06478043 🔗 asco.org/abstracts-pres… @OncoAlert @Larvol @ASCO
Hidehito HORINOUCHI tweet media
Hidehito HORINOUCHI@HHorinouchi

🆙 #ASCO26 #LCSM Oral Abstract Session 🔥Ivonescimab Plus Liposomal Irinotecan in SCLC Progressing after First-Line Chemoimmunotherapy 🎙️Dr. Yun Fan 🔢8007 ☑️NCT06478043 🔗 asco.org/abstracts-pres… @OncoAlert @Larvol @ASCO

English
0
9
20
3.6K
AMRANE Karim retweetledi
Dr Rishabh Jain
Dr Rishabh Jain@DrRishabhOnco·
🩺 THE 10 MOST IMPORTANT GI CANCER TRIALS OF #ASCO26 🌟 PLENARY & PRACTICE-CHANGERS 1️⃣ RASolute 302 (LBA5) Daraxonrasib (RMC-6236) vs chemotherapy in metastatic pancreatic cancer Can RAS finally become druggable in pancreatic cancer? 2️⃣ CIRCULATE (LBA3500) ctDNA-guided adjuvant therapy in stage II colon cancer Potentially the defining trial for escalation and de-escalation strategies. 3️⃣ EMERALD-3 Durvalumab + tremelimumab + lenvatinib + TACE in unresectable HCC How aggressive should frontline liver cancer therapy become? 🧬 COLORECTAL CANCER PRECISION ERA 4️⃣ BREAKWATER Cohort 3 (LBA3503) Encorafenib + cetuximab + FOLFIRI in BRAF V600E mCRC Important real-world sequencing data beyond oxaliplatin-based therapy. 5️⃣ SWOG S2107 Sequencing optimization in BRAF V600E metastatic CRC A major unmet-need clinical question. 6️⃣ STELLAR Update Long-term survival update for TNT in rectal cancer Do pCR gains translate into durable survival benefit? 🎯 GASTRIC, GEJ & RARE GI SUBTYPES 7️⃣ HERIZON-GEA-01 (4010) Zanidatamab-based frontline therapy in HER2+ gastric/GEJ cancer Could bispecific HER2 targeting redefine frontline care? 8️⃣ KEYNOTE-811 Mature OS Final long-term OS update for pembrolizumab + trastuzumab + chemotherapy Clinicians have been waiting for these mature survival curves. 9️⃣ ATTRACTION-6 Update Checkpoint inhibitor strategies in advanced gastroesophageal cancers The IO sequencing debate continues. 🔟 Bezuclastinib + Sunitinib (11500) Phase III data in advanced GIST A key resistance-targeting strategy in rare GI oncology. Which GI abstract will change your clinic most? #GIOnc #OncTwitter #ASCO26 #PanCan #ColorectalCancer #MedTwitter @ASCO @myesmo @esmo_open @OncoAlert
Dr Rishabh Jain tweet media
Dr Rishabh Jain@DrRishabhOnco

🚨 THE 15 MOST IMPORTANT TRIALS OF #ASCO26 May 29 - June 2 | Chicago Which trial are you watching most closely? 🌟 PLENARY GAME-CHANGERS 1️⃣ PROTEUS Perioperative apalutamide + ADT in high-risk localized prostate cancer 2️⃣ LIBRETTO-432 Adjuvant selpercatinib in RET+ NSCLC 3️⃣ HARMONi-6 Ivonescimab + chemo vs tislelizumab + chemo in squamous NSCLC 4️⃣ RASolute 302 Daraxonrasib (RMC-6236) in metastatic pancreatic cancer 5️⃣ SARC041 Abemaciclib in dedifferentiated liposarcoma ⚡ FRONTLINE & PERIOPERATIVE SHIFTS 6️⃣ KEYNOTE-B15 / EV-304 EV + pembrolizumab vs chemo in MIBC 7️⃣ LITESPARK-022 Pembrolizumab + belzutifan in adjuvant ccRCC 8️⃣ AMBITION Paclitaxel/bevacizumab ± atezolizumab in HR+ breast cancer 9️⃣ NeoADAURA Neoadjuvant osimertinib in EGFR+ NSCLC 🔟 A-DREAM ADT interruption strategies in mCSPC 🧬 PRECISION, ADCs & NEXT-GEN IMMUNOLOGY 1️⃣1️⃣ DESTINY-Breast06 T-DXd expands into HER2-ultralow disease 1️⃣2️⃣ CROWN (7-year update) Lorlatinib durability in ALK+ NSCLC 1️⃣3️⃣ DeLLphi-312 Tarlatamab in frontline SCLC 1️⃣4️⃣ COMMIT Atezolizumab + FOLFOX/Bev in MSI-H mCRC 1️⃣5️⃣ IMvigor011 ctDNA-guided adjuvant atezolizumab in bladder cancer #OncoTwitter #MedTwitter #ASCO26 #CancerResearch @OncoAlert @ASCO @JCOPO_ASCO @OncBrothers

English
0
51
124
13.6K
AMRANE Karim retweetledi
Aakash Desai, MD, MPH, FASCO
Aakash Desai, MD, MPH, FASCO@ADesaiMD·
#ASCO26 #ANVIL is in. ➡️Adjuvant nivolumab: negative. DFS HR 0.97, p=0.78. N=935. 6 years of follow-up. PD-L1≥50%: HR 0.86, p=0.43. But here's what makes this problematic; put it next to IMpower010 and KEYNOTE-091: PD-L1≥50%: • IMpower010 (atezo): HR 0.43 ✓ • KEYNOTE-091 (pembro): HR 0.82 ✗ • ANVIL (nivo): HR 0.86 ✗ PD-L1<1%: • IMpower010: HR 0.97 ✗ • KEYNOTE-091: HR 0.75 ✓ • ANVIL: HR 0.97 ✗ Three drugs. Three assays. Completely inconsistent results by PD-L1 subgroup. No reproducible biomarker-efficacy relationship across trials. I do not think this is a nivolumab problem. It's an adjuvant IO problem. We don't understand which patients benefit and after 3 phase IIIs, we still can't reliably select them. ctDNA-guided adjuvant therapy can't come fast enough. @ASCO @LungCancerRx
Aakash Desai, MD, MPH, FASCO tweet media
English
1
13
46
2.7K
AMRANE Karim retweetledi
Hidehito HORINOUCHI
Hidehito HORINOUCHI@HHorinouchi·
🆙 #ASCO26 #LCSM Oral 🔥CHRYSALIS-2: 1L Ami-Laz in Atypical EGFR-Mutated Advanced NSCLC ✅mOS 41.0m ✅3-yr OS 55%, 4-yr OS 46% ✅20% still on 1L tx (up to 4.4yr) 🎙️ @JoelNealMD 🔢8501 ☑️NCT04077463 🔗 asco.org/abstracts-pres… @OncoAlert @Larvol @ASCO @EGFRResisters @Exon20Group
Hidehito HORINOUCHI tweet media
Hidehito HORINOUCHI@HHorinouchi

🆙 #ASCO26 #LCSM Oral Abstract Session 🔥CHRYSALIS-2: Overall Survival of First-Line Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced NSCLC 🎙️Dr. Joel W. Neal 🔢8501 ☑️NCT04077463 🔗 asco.org/abstracts-pres… @OncoAlert @Larvol @ASCO

English
1
9
18
1.6K
AMRANE Karim retweetledi
Dr Rishabh Jain
Dr Rishabh Jain@DrRishabhOnco·
🚨 Can we finally stop prolonged maintenance chemotherapy in HR+/HER2- metastatic breast cancer after response to first-line chemo? The phase III FAMILY trial just delivered a strong signal. 👇 🧪 HR+/HER2- MBC patients with disease control after first-line chemotherapy were randomized to: 🔹 Fulvestrant maintenance vs 🔸 Capecitabine maintenance 👥 210 patients 🌍 22 centers across China ⚠️ ~60% had clinically aggressive disease 📊 Key results: ✅ Median PFS • Fulvestrant: 17.3 months • Capecitabine: 9.0 months HR 0.63; p=0.003 ✅ Total PFS • 22.2 vs 14.4 months ✅ Benefit maintained even in clinically aggressive disease 🩺 Toxicity favored fulvestrant: • Grade ≥3 AEs: 2.9% vs 10.5% • Hand-foot syndrome: 2.9% vs 42.9% • No AE-related discontinuations with fulvestrant ⚠️ OS data still immature. Important nuance: This was largely a pre-CDK4/6 inhibitor era population, so applicability in modern CDK4/6-pretreated patients remains uncertain. Still, this is highly relevant for: 🌍 Resource-limited settings 💰 Patients without CDK4/6 access ⚡ Patients started on chemotherapy for aggressive disease needing rapid response Could endocrine maintenance after short-course chemotherapy become a more pragmatic strategy in real-world HR+ MBC? 📖 Full paper in comment ⬇️ #OncoTwitter #MedTwitter #BreastCancer #bcsm @myesmo @asco @ESMO_Open @OncoAlert
Dr Rishabh Jain tweet media
English
1
22
55
3.3K
AMRANE Karim retweetledi
Paolo Tarantino
Paolo Tarantino@PTarantinoMD·
The most important breast abstract from #ASCO26 is out. 4429 pts with ER+/HER2- BC randomized to SoC vs PAM50-directed adjuvant treatment. 19% had N2 dz (4-9 nodes), premenopausal pts received LHRHa. No benefit from chemo if ROR≤60. Looking forward to the full presentation.
Paolo Tarantino tweet media
ASCO@ASCO

#ASCO26 abstracts have dropped! 🎉 Explore over 7,000 newly available studies showcasing the latest breakthroughs transforming global cancer care: bit.ly/3PAl4Qo

English
6
43
124
15.8K
AMRANE Karim retweetledi
Pierre Blanchard, MD
Pierre Blanchard, MD@PBlanchardMD·
Yesterday, I presented the @GETUG_Unicancer PEACE 2 trial at #ESTRO26 on the role of pelvic RT in very high risk #prostatecancer pts (staged with conventional imaging). Twittorial below Key conclusion: pelvic RT did not improve clinical outcomes (cPFS, MFS, PCSS, OS)... 1/n
Pierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet media
English
7
84
147
16.6K
AMRANE Karim retweetledi
Pierre Blanchard, MD
Pierre Blanchard, MD@PBlanchardMD·
The HEAT trial is another randomized demonstration of the safety & efficacy of SBRT compared to hypofractionted RT in #prostatecancer at #ESTRO26
Pierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet media
English
2
27
60
3.5K

Keşfet

@asco @myesmo @esmo_open @OncoAlert @larvol @ASCO @JuliaRotow @ONealCancerUAB